Fredag 15 Augusti | 05:57:05 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-25 08:30 Bokslutskommuniké 2025
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-08-28 08:00 Kvartalsrapport 2025-Q2
2025-06-16 - Årsstämma
2025-05-15 - X-dag ordinarie utdelning LIPUM 0.00 SEK
2025-04-24 - Kvartalsrapport 2025-Q1
2025-02-26 - Bokslutskommuniké 2024
2024-10-25 - Kvartalsrapport 2024-Q3
2024-08-09 - Kvartalsrapport 2024-Q2
2024-05-29 - X-dag ordinarie utdelning LIPUM 0.00 SEK
2024-05-28 - Årsstämma
2024-05-28 - Kvartalsrapport 2024-Q1
2024-04-02 - Extra Bolagsstämma 2024
2024-02-29 - Bokslutskommuniké 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-06-27 - Extra Bolagsstämma 2023
2023-05-11 - X-dag ordinarie utdelning LIPUM 0.00 SEK
2023-05-10 - Årsstämma
2023-04-25 - Kvartalsrapport 2023-Q1
2023-03-24 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-10-12 - Extra Bolagsstämma 2022
2022-07-27 - Kvartalsrapport 2022-Q2
2022-05-18 - Kvartalsrapport 2022-Q1
2022-04-27 - X-dag ordinarie utdelning LIPUM 0.00 SEK
2022-04-26 - Årsstämma
2022-03-25 - Bokslutskommuniké 2021
2021-12-22 - Extra Bolagsstämma 2021
2021-11-26 - Kvartalsrapport 2021-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Lipum är ett biofarmaceutiskt bolag. Bolaget är i klinisk fas och specialiserade på upptäckt och utveckling av nya behandlingar för kroniska inflammatoriska sjukdomar. Bolagets läkemedelskandidat är baserad på en antikropp som ämnar användas i behandlingar för att blockera en specifik molekyl i immunförsvaret. Läkemedelskandidaten är i klinisk fas med prekliniska data för reumatism. Bolaget utvärderar även andra inflammatoriska sjukdomar. Lipum har sin verksamhet i Umeå.
2025-08-07 08:30:00

Lipum AB (publ) has appointed Tobias Helgesson as its new Chief Financial Officer (CFO). He succeeds Marina Norberg, who will remain with the company during a transitional period to ensure continuity and a smooth handover.

Tobias Helgesson holds a bachelor’s degree in business administration from Lund University. He brings over 20 years of professional experience, including more than 11 years in the pharmaceutical industry, having worked for companies such as Pfizer, Sanofi, and Otsuka Pharmaceutical. Tobias has held roles including Business Controller, Financial Controller, Finance Manager, and CFO. Through these positions, he has built a solid foundation of experience and a broad skill set, making him well-equipped for the CFO role at Lipum.

“I am very pleased to join Lipum, which I see as a highly interesting company in an exciting phase. It is truly inspiring to be part of an organization so dedicated to making a difference for patients. I very much look forward to working with the Lipum team,” says Tobias Helgesson.

Marina is leaving Lipum at her own request.

“I’ve had the privilege of working with Marina during my two years at Lipum. Her experience and dedication have made her a highly valued colleague, and I want to extend my sincere thanks to her. At the same time, I’m very pleased to welcome Tobias to Lipum. He brings a broad and valuable skill set, and his experience from various pharmaceutical companies, combined with strong engagement and a hands-on approach, will be an important addition to our team,” says CEO Ola Sandborgh.